Pharm-Olam International, a multinational, full-service CRO serving the biopharmaceutical and medical device industries, has announced the appointment of Daniel Burgess to the position of Senior Director, Quality and Compliance.
“In clinical trials, Quality Assurance and Compliance considerations go hand-in-hand,” said Sanjiv Suri, chief executive officer, Pharm-Olam. “Over two decades, Pharm-Olam earned its reputation among drug developers as a high quality, responsive partner who can adapt its services to the unique requirements of each study. I’m confident Daniel will continue to lead that charge.”
Burgess’ extensive experience was a key factor in his appointment, Suri added. He brings to Pharm-Olam over 25 years of experience in the critical areas of quality assurance, quality control, auditing and compliance. Mr. Burgess’ resume includes progressive roles within several leading pharmaceutical industry organizations including Ipsen, Novartis, Alexion, Thermo Fisher Scientific and Pfizer.
Pharm-Olam operates in more than 60 countries worldwide, offering end-to-end clinical trial support for Phase I-IV clinical trials.